8.03
0.04 (0.50%)
| Penutupan Terdahulu | 7.99 |
| Buka | 8.07 |
| Jumlah Dagangan | 165,108 |
| Purata Dagangan (3B) | 258,511 |
| Modal Pasaran | 725,296,064 |
| Harga / Pendapatan (P/E TTM) | 401.50 |
| Harga / Jualan (P/S) | 8.63 |
| Harga / Buku (P/B) | 11.27 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 Aug 2025 - 15 Aug 2025 |
| Margin Keuntungan | 7.20% |
| Margin Operasi (TTM) | 10.31% |
| EPS Cair (TTM) | 0.020 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -18.80% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -64.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.52% |
| Nisbah Semasa (MRQ) | 3.60 |
| Aliran Tunai Operasi (OCF TTM) | -6.65 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -8.55 M |
| Pulangan Atas Aset (ROA TTM) | 5.18% |
| Pulangan Atas Ekuiti (ROE TTM) | 12.12% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Gyre Therapeutics, Inc. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -2.5 |
| Purata | -0.75 |
|
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 91.25% |
| % Dimiliki oleh Institusi | 2.99% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Advantage Alpha Capital Partners Lp | 31 Mar 2025 | 13,663 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Purata Hasil Dividen 3T | 6.31% |
| Tarikh EX | Tarikh Pengumuman | Tarikh Pembayaran | Perincian |
|---|---|---|---|
| 13 Jan 2023 | 26 Dec 2022 | 12 Jan 2023 | 0.24 Tunai |
| 21 Sep 2022 | 24 Aug 2022 | 20 Sep 2022 | 1.43 Tunai |
| 20 Aug 2015 | 04 Aug 2015 | 19 Aug 2015 | 1.6492 Tunai |
Hasil Dividen Tahunan
| Tahun | Dividen Tahunan ($) | Kekerapan/Tahun | Hasil % |
|---|---|---|---|
| 2023 | 0.240 | 1 | 0.93 |
| 2022 | 1.43 | 1 | 17.99 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |